



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 104472

TO: Christine Saoud
Location: CM1/10E03&10B19
Art Unit: 1647
Thursday, September 25, 2003

Case Serial Number: 09/905348

From: Barb O'Bryen
Location: Biotech-Chem Library
CM1-6A05
Phone: 308-4291
barbara.obryen@uspto.gov

A handwritten signature in black ink that appears to read "Bob" or "Barbara".

Search Notes

RUSH

					GenCore version 5.1.6
					Copyright (c) 1993 - 2003 Compugen Ltd.
					OM protein - protein search, using sw model
Run on:	September 24, 2003, 18:05:48	(without alignments)	Search time 41 Seconds		
Scoring table:	BLOSUM62	731.691 Million cell	updates/sec		
Title:	US-09-905-348-1B				
Perfect score:	1045				
Sequence:	1 MTHRTTWARTRSAVTPC..... QVNSVVPAPSRGQALRRAQ 189				
Searched:	1107863 seqs, 158726573 residues				
Total number of hits satisfying chosen parameters:	1107863				
Minimum DB seq length:	0				
Maximum DB seq length:	2000000000				
Post-processing:	Minimum Match 0%				
Maximum Match 100%					
Listing first 45 summaries					
Database :					
1: /SIDS1/gcdata/geneseq/geneseq-emb1/AA1900.DAT:*					
2: /SIDS1/gcdata/geneseq/geneseq-emb1/AA1901.DAT:*					
3: /SIDS1/gcdata/geneseq/geneseq-emb1/AA1902.DAT:*					
4: /SIDS1/gcdata/geneseq/geneseq-emb1/AA1903.DAT:*					
5: /SIDS1/gcdata/geneseq/geneseq-emb1/AA1904.DAT:*					
6: /SIDS1/gcdata/geneseq/geneseq-emb1/AA1905.DAT:*					
7: /SIDS1/gcdata/geneseq/geneseq-emb1/AA1906.DAT:*					
8: /SIDS1/gcdata/geneseq/geneseq-emb1/AA1907.DAT:*					
9: /SIDS1/gcdata/geneseq/geneseq-emb1/AA1908.DAT:*					
10: /SIDS1/gcdata/geneseq/geneseq-emb1/AA1909.DAT:*					
11: /SIDS1/gcdata/geneseq/geneseq-emb1/AA1910.DAT:*					
12: /SIDS1/gcdata/geneseq/geneseq-emb1/AA1991.DAT:*					
13: /SIDS1/gcdata/geneseq/geneseq-emb1/AA1992.DAT:*					
14: /SIDS1/gcdata/geneseq/geneseq-emb1/AA1993.DAT:*					
15: /SIDS1/gcdata/geneseq/geneseq-emb1/AA1994.DAT:*					
16: /SIDS1/gcdata/geneseq/geneseq-emb1/AA1995.DAT:*					
17: /SIDS1/gcdata/geneseq/geneseq-emb1/AA1996.DAT:*					
18: /SIDS1/gcdata/geneseq/geneseq-emb1/AA1997.DAT:*					
19: /SIDS1/gcdata/geneseq/geneseq-emb1/AA1998.DAT:*					
20: /SIDS1/gcdata/geneseq/geneseq-emb1/AA1999.DAT:*					
21: /SIDS1/gcdata/geneseq/geneseq-emb1/AA2000.DAT:*					
22: /SIDS1/gcdata/geneseq/geneseq-emb1/AA2001.DAT:*					
23: /SIDS1/gcdata/geneseq/geneseq-emb1/AA2002.DAT:*					
24: /SIDS1/gcdata/geneseq/geneseq-emb1/AA2003.DAT:*					
Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.					
					SUMMARIES
Result No.	Score	Query	Match Length	DB ID	Description
1	1045	100.0	189	22	AAB80215
2	1045	100.0	189	24	ABU69625
3	1045	100.0	189	24	ABU71443
4	1045	100.0	189	24	ABU71894
5	1045	100.0	189	24	ABU67348
6	1045	100.0	189	24	ABU64502
7	1045	100.0	189	24	ABU54350
8	998	95.5	187	20	AAV66174
9	119	11.4	1518	24	ABJ18375
					ALIGNMENTS
					RESULT 1
					AB80215
					ID AAB80215 standard; Protein; 189 AA.
					XX
					AC AAB80215;
					XX
					DT 24-APR-2001 (first entry)
					XX
					DE Human PRO232_protein.
					XX
					KW Human; PRO; dermatological; antipsoriatic; cytostatic; antiinflammatory; antiparkinsonian nootropic; neuroprotective; vulnerary; cardiotonic; antiangiogenic; vasoconstrictive; antiasthmatic; antirheumatic; cancer; antiarthritic; antiinfertility; antidiabetic; antiviral; diabetes; ophthalmological; gene therapy; skin disease; gastrointestinal disorder; ischaemia; inflammation.
					KW OS Homo sapiens.
					XX
					PN WO200104311-A1.
					XX
					PD 18-JAN-2001.
					XX
					PF 22-FEB-2000; 2000WO-US04414.
					XX
					PR 07-JUL-1999; 990US-0143048.
					PR 26-JUL-1999; 990US-0145698.
					PR 28-JUL-1999; 990US-0146222.
					PR 08-SEP-1999; 990US-050594.
					PR 13-SEP-1999; 990US-050944.
					PR 15-SEP-1999; 990US-1090.
					PR 15-SEP-1999; 990US-21547.

PR 05-OCT-1999; 99WO-US23089.
 PR 29-NOV-1999; 99WO-US28214.
 PR 30-NOV-1999; 99WO-US28313.
 PR 16-DEC-1999; 99WO-US3005.
 PR 20-DEC-1999; 99WO-US30911.
 PR 20-DEC-1999; 99WO-US3099.
 PR 05-JAN-2000; 99WO-US0219.
 XX
 PA (GETH) GENENTECH INC.
 PI Ashkenazi AJ, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Goddard A, Godowski PJ, Grimaldi CJ, Gurney AL, Hillan KJ, Kijavin IJ, Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Williams PM, Wood WI; PI WPI; DR DR; XX
 DR WPI; 2001-081051/09.
 XX N-PSDB; AAF72374.
 PT Sixty one nucleic acids encoding PRO polypeptides which are useful in the treatment of skin diseases (e.g. psoriasis), cancers (e.g. lung squamous cell carcinoma) and neurodegenerative diseases (e.g. Alzheimer's disease).
 PS Claim 1; Fig 9; 393pp; English.
 XX
 CC The present sequence is one of sixty one novel secreted and transmembrane PRO polypeptides are useful for treating skin diseases (e.g. psoriasis), cancers (e.g. lung squamous cell carcinoma), gastrointestinal disorders (e.g. enterocolitis), neurodegenerative diseases (e.g. Alzheimer's disease, Parkinson's disease), wound repair, cardiovascular disorders (e.g. endometrial bleeding angiogenesis, ischaemias such as coronary ischaemia, atherosclerosis), inflammatory disorders (e.g. asthma, rheumatoid arthritis, multiple sclerosis), infertility, AIDS and diabetes and retinal disorders such as retinitis pigmentosum. The PRO nucleic acids have applications in molecular biology, including use as hybridization probes, and in chromosome and gene mapping.
 CC Sequence 189 AA;
 CC
 Query Match 100.0%; Score 1045; DB 22; Length 189;
 Best Local Similarity 100.0%; Pred No. 5.3e-86; Matches 189; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 CC
 OQ 1 MTHRTTWTWARTSRAVTPTCATPAPMPMCRLPPSLRCLHSACCSGDRASRYRQAGPLQ 60
 DB 1 MTHRTTWTWARTSRAVTPTCATPAPMPMCRLPPSLRCLHSACCSGDRASRYRQAGPLQ 60
 OQ 61 PTIGYVPOASVPLTLAQEMPVLYPEAHNDSLTMVCTPVPHDPPMALSRTPTQIS 120
 DB 61 PTIGYVPOASVPLTLAQEMPVLYPEAHNDSLTMVCTPVPHDPPMALSRTPTQIS 120
 OQ 181 RGOALRRAQ 189
 DB 181 RGOALRRAQ 189
 RESULT 2
 ABU69625 standard; Protein; 189 AA.
 AC ABU69625;
 DT 05-JUN-2003 (first entry)
 DE Novel human secreted and transmembrane protein PRO232.
 XX Human; secreted and transmembrane protein; gene therapy; psoriasis;

XX
 PR Homo sapiens.
 XX OS
 PR US2003017463-A1.
 XX PN
 PR 23-JAN-2003.
 PD XX
 PR 11-JUL-2001; 2001US-0903640.
 PR XX
 PR 10-SEP-1998; 99WO-US18824.
 PR 14-SEP-1998; 99WO-US19177.
 PR 16-SEP-1998; 99WO-US19330.
 PR 17-SEP-1998; 99WO-US19437.
 PR 01-DEC-1998; 99WO-US25108.
 PR 08-SEP-1999; 99WO-US20394.
 PR 13-SEP-1999; 99WO-US20944.
 PR 15-SEP-1999; 99WO-US21547.
 PR 15-SEP-1999; 99WO-US23089.
 PR 29-NOV-1999; 99WO-US28214.
 PR 30-NOV-1999; 99WO-US28313.
 PR 01-DEC-1999; 99WO-US28301.
 PR 02-DEC-1999; 99WO-US28364.
 PR 02-DEC-1999; 99WO-US28565.
 PR 16-DEC-1999; 99WO-US30095.
 PR 20-DEC-1999; 99WO-US30311.
 PR 20-DEC-1999; 99WO-US30399.
 PR 05-JAN-2000; 2000WO-US00219.
 PR 11-FEB-2000; 2000WO-US03565.
 PR 22-FEB-2000; 2000WO-US0414.
 PR 24-FEB-2000; 2000WO-US0004.
 PR 02-MAR-2000; 2000WO-US05841.
 PR 20-MAR-2000; 2000WO-US0377.
 PR 22-MAY-2000; 2000WO-US1042.
 PR 02-JUN-2000; 2000WO-US1264.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 17-SEP-1997; 97US-059113P.
 PR 17-SEP-1997; 97US-059115P.
 PR 17-SEP-1997; 97US-059117P.
 PR 17-SEP-1997; 97US-059119P.
 PR 17-SEP-1997; 97US-059121P.
 PR 17-SEP-1997; 97US-059122P.
 PR 17-SEP-1997; 97US-059184P.
 PR 18-SEP-1997; 97US-059263P.
 PR 15-OCT-1997; 97US-062125P.
 PR 17-OCT-1997; 97US-062285P.
 PR 17-OCT-1997; 97US-062287P.
 PR 21-OCT-1997; 97US-063486P.
 PR 24-OCT-1997; 97US-062814P.
 PR 24-OCT-1997; 97US-063816P.
 PR 24-OCT-1997; 97US-063045P.
 PR 24-OCT-1997; 97US-063120P.
 PR 24-OCT-1997; 97US-063127P.
 PR 24-OCT-1997; 97US-063128P.
 PR 27-OCT-1997; 97US-063327P.
 PR 27-OCT-1997; 97US-063329P.
 PR 28-OCT-1997; 97US-063541P.
 PR 28-OCT-1997; 97US-063542P.
 PR 28-OCT-1997; 97US-063544P.
 PR 28-OCT-1997; 97US-063550P.
 PR 28-OCT-1997; 97US-063554P.

KW enterocolitis; gastrointestinal ulceration; skin disease;
 KW keratinocyte differentiation; epithelial cancer; Alzheimer's disease;
 KW squamous cell carcinoma; Parkinson's disease; inflammatory disease;
 KW amyotrophic lateral sclerosis; rheumatoid arthritis; asthma;
 KW multiple sclerosis; organ failure; atherosclerosis; cardiac injury;
 KW infertility; birth defect; premature aging; AIDS; cancer;
 KW diabetic complication; wound repair; tissue re-growth.

		Query	Match	Score	DB	Length	189;
PR	29-OCT-1997;	97US-063435P.					
PR	29-OCT-1997;	97US-063704P.					
PR	29-OCT-1997;	97US-063732P.					
PR	29-OCT-1997;	97US-063734P.					
PR	29-OCT-1997;	97US-063735P.					
PR	29-OCT-1997;	97US-063738P.					
PR	29-OCT-1997;	97US-064215P.					
PR	31-OCT-1997;	97US-063870P.					
PR	31-OCT-1997;	97US-064103P.					
PR	03-NOV-1997;	97US-064248P.					
PR	07-NOV-1997;	97US-064809P.					
PR	12-NOV-1997;	97US-065186P.					
PR	17-NOV-1997;	97US-06546P.					
PR	18-NOV-1997;	97US-065693P.					
PR	21-NOV-1997;	97US-066120P.					
PR	24-NOV-1997;	97US-066364P.					
PR	24-NOV-1997;	97US-066772P.					
PR	24-NOV-1997;	97US-066940P.					
PR	12-DEC-1997;	97US-069425P.					
PR	04-JUN-1998;	98US-088026P.					
PR	10-SEP-1998;	98US-099803P.					
PR	14-SEP-1998;	98US-100262P.					
PR	17-SEP-1998;	98US-10058P.					
PR	13-OCT-1998;	98US-104080P.					
PR	20-NOV-1998;	98US-10904P.					
PR	22-DEC-1998;	98US-113296P.					
PR	07-JUL-1999;	99US-143048P.					
PR	26-JUL-1999;	99US-14598P.					
PR	28-JUL-1999;	99US-14622P.					
PR	18-SEP-2000;	2000US-0665350.					
XX							
PA	(GERTH) GENENTECH INC.						
XX							
PT	Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillian KJ, Kjavian LJ, Mather JP, Pan J, Paoni NF, Roy MA, Williams PM, Wood WI, Williams PM, Wood WI;	PI	PI	PI	PI	PI	XX
XX							
DR	WPI: 2003-341586/32.						
XX							
PT	New PRO polypeptides and nucleic acid molecules, useful in diagnosing or treating inflammatory diseases, organ failure, atherosclerosis, cardiac injury, infertility, cancer, AIDS, Alzheimer's disease or Parkinson's disease -						
XX							
PS	Claim 12; FIG 9; 473PP; English.						
XX							
CC	The invention describes sixty one nucleic acids encoding PRO polypeptides (secreted and transmembrane). The PRO polypeptides and nucleic acids are useful in diagnosing or treating enterocolitis, gastrointestinal ulceration, skin diseases associated with abnormal keratinocyte differentiation, e.g. psoriasis or epithelial cancers such as squamous cell carcinoma, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, inflammatory diseases, e.g. rheumatoid arthritis, injury, infertility, birth defects, premature aging, AIDS, cancer, diabetic complications, or mutations in general. The polypeptides are also useful for wound repair and associated therapies concerned with re-growth of tissue. The PRO polypeptides and nucleic acid molecules are also useful in gene therapy, and as molecular weight markers for protein electrophoresis purposes. The anti-PRO antibodies may be used in diagnostic assays for PRO, or for the affinity purification of PRO from recombinant cell culture or natural sources. This is the amino acid sequence of a novel human PRO polypeptide.						
XX							
SQ	Sequence 189 AA;						
PR	29-OCT-1997;	97US-063435P.	Query	Match	100.0%	Score	1045;
PR	29-OCT-1997;	97US-063704P.	Best	Local Similarity	100.0%	Pred. No.	5.3e-86;
PR	29-OCT-1997;	97US-063732P.	Matches	189;	Conservative	0;	Mismatches 0;
PR	29-OCT-1997;	97US-063734P.	Indels	0;	Indels	0;	Indels 0;
PR	29-OCT-1997;	97US-063735P.	Matches	189;	Conservative	0;	Mismatches 0;
PR	29-OCT-1997;	97US-063738P.	Indels	0;	Indels	0;	Indels 0;
PR	29-OCT-1997;	97US-064215P.	Matches	189;	Conservative	0;	Mismatches 0;
PR	31-OCT-1997;	97US-063870P.	Indels	0;	Indels	0;	Indels 0;
PR	31-OCT-1997;	97US-064103P.	Matches	189;	Conservative	0;	Mismatches 0;
PR	03-NOV-1997;	97US-064248P.	Indels	0;	Indels	0;	Indels 0;
PR	07-NOV-1997;	97US-064809P.	Matches	189;	Conservative	0;	Mismatches 0;
PR	12-NOV-1997;	97US-065186P.	Indels	0;	Indels	0;	Indels 0;
PR	17-NOV-1997;	97US-06546P.	Matches	189;	Conservative	0;	Mismatches 0;
PR	18-NOV-1997;	97US-065693P.	Indels	0;	Indels	0;	Indels 0;
PR	21-NOV-1997;	97US-066120P.	Matches	189;	Conservative	0;	Mismatches 0;
PR	24-NOV-1997;	97US-066364P.	Indels	0;	Indels	0;	Indels 0;
PR	24-NOV-1997;	97US-066772P.	Matches	189;	Conservative	0;	Mismatches 0;
PR	24-NOV-1997;	97US-066940P.	Indels	0;	Indels	0;	Indels 0;
PR	12-DEC-1997;	97US-069425P.	Matches	189;	Conservative	0;	Mismatches 0;
PR	04-JUN-1998;	98US-088026P.	Indels	0;	Indels	0;	Indels 0;
PR	10-SEP-1998;	98US-099803P.	Matches	189;	Conservative	0;	Mismatches 0;
PR	14-SEP-1998;	98US-100262P.	Indels	0;	Indels	0;	Indels 0;
PR	17-SEP-1998;	98US-10058P.	Matches	189;	Conservative	0;	Mismatches 0;
PR	13-OCT-1998;	98US-104080P.	Indels	0;	Indels	0;	Indels 0;
PR	20-NOV-1998;	98US-10904P.	Matches	189;	Conservative	0;	Mismatches 0;
PR	22-DEC-1998;	98US-113296P.	Indels	0;	Indels	0;	Indels 0;
PR	07-JUL-1999;	99US-143048P.	Matches	189;	Conservative	0;	Mismatches 0;
PR	26-JUL-1999;	99US-14598P.	Indels	0;	Indels	0;	Indels 0;
PR	28-JUL-1999;	99US-14622P.	Matches	189;	Conservative	0;	Mismatches 0;
PR	18-SEP-2000;	2000US-0665350.	Indels	0;	Indels	0;	Indels 0;
XX							
PA	(GERTH) GENENTECH INC.						
XX							
PT	Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillian KJ, Kjavian LJ, Mather JP, Pan J, Paoni NF, Roy MA, Williams PM, Wood WI, Williams PM, Wood WI;	PI	PI	PI	PI	PI	XX
XX							
PR	07-SEP-1998;	98WO-US18824.	DE	Human PRO polypeptide #4.			
PR	14-SEP-1998;	98WO-US19177.	XX				
PR	16-SEP-1998;	98WO-US19330.	XX				
PR	17-SEP-1998;	98WO-US19437.	XX				
PR	01-DEC-1998;	98WO-US25108.	XX				
PR	08-SEP-1999;	99WO-US20594.	XX				
PR	13-SEP-1999;	99WO-US20944.	XX				
PR	15-SEP-1999;	99WO-US21090.	XX				
PR	15-SEP-1999;	99WO-US21547.	XX				
PR	20-DEC-1999;	99WO-US22089.	XX				
PR	01-DEC-1999;	99WO-US2301.	XX				
PR	02-DEC-1999;	99WO-US24564.	XX				
PR	16-DEC-1999;	99WO-US2565.	XX				
PR	22-FEB-2000;	2000WO-US0414.	XX				
PR	28-JUL-2000;	2000WO-US20710.	XX				
PR	24-AUG-2000;	2000WO-US23328.	XX				
PR	17-SEP-1997;	97US-059113P.	XX				
PR	17-SEP-1997;	97US-059115P.	XX				
PR	17-SEP-1997;	97US-059117P.	XX				
PR	18-SEP-1997;	97US-059266P.	XX				
PR	15-OCT-1997;	97US-062125P.	XX				
PR	17-OCT-1997;	97US-062285P.	XX				
PR	21-OCT-1997;	97US-06287P.	XX				
PR	24-OCT-1997;	97US-06386P.	XX				
PR	24-OCT-1997;	97US-062814P.	XX				

PR 24-OCT-1997; 97US-062816P.

XX XX PA (GETH) GENENTECH INC.

XX XX PA

PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N; PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A; PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Klijavins IJ; PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D; PI Williams PM, Wood WI;

XX DR WPI: 2003-361832/34.

DR N-PSDB; ACA58306.

XX DR

PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO245 or PRO1868, useful in molecular biology, chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy

XX PT

PS Claim 12; Fig 9; 474pp; English.

CC The present invention relates to the isolation of novel human secreted and transmembrane proteins (PRO polypeptides), and the polynucleotide sequences encoding them. The polynucleotide sequences are useful in molecular biology, as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy. The polynucleotide sequences may also be used in preparing PRO polypeptides by recombinant techniques, and in generating either transgenic animals or knock-out animals which, in turn, are useful in the development and screening of therapeutic reagents. The PRO polypeptides or their antibodies are useful in preparing a medicament for treating a condition responsive to the polypeptide or antibody, such as cancer, Alzheimer's disease or ischaemia, and in various diagnostic assays. ABU71445-ABU71505 represent human PRO polypeptides of the invention.

XX Sequence 189 AA;

Query Match 100.0%; Score 10/15; DB 24; Length 189;

Best Local Similarity 100.0%; Pred No. 5.3e-86; Matches 189; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY

1 MTHRHTTWWARTSRASVTPCATPAGPMPMSRLPSLRLSACCGSDPASYRLGAPQ 60

1 MTHRHTTWWARTSRASVTPCATPAGPMPMSRLPSLRLSACCGSDPASYRLGAPQ 60

61 PTIGVYPOASVPLTLAQWEPVLPYPEAHNPASLTMVYOTPVPHDPMPMSRLSPTQTS 120

61 PTIGVYPOASVPLTLAQWEPVLPYPEAHNPASLTMVYOTPVPHDPMPMSRLSPTQTS 120

62 PTIGVYPOASVPLTLAQWEPVLPYPEAHNPASLTMVYOTPVPHDPMPMSRLSPTQTS 120

62 PTIGVYPOASVPLTLAQWEPVLPYPEAHNPASLTMVYOTPVPHDPMPMSRLSPTQTS 120

63 PTIGVYPOASVPLTLAQWEPVLPYPEAHNPASLTMVYOTPVPHDPMPMSRLSPTQTS 120

63 PTIGVYPOASVPLTLAQWEPVLPYPEAHNPASLTMVYOTPVPHDPMPMSRLSPTQTS 120

64 PTIGVYPOASVPLTLAQWEPVLPYPEAHNPASLTMVYOTPVPHDPMPMSRLSPTQTS 120

64 PTIGVYPOASVPLTLAQWEPVLPYPEAHNPASLTMVYOTPVPHDPMPMSRLSPTQTS 120

65 PTIGVYPOASVPLTLAQWEPVLPYPEAHNPASLTMVYOTPVPHDPMPMSRLSPTQTS 120

65 PTIGVYPOASVPLTLAQWEPVLPYPEAHNPASLTMVYOTPVPHDPMPMSRLSPTQTS 120

66 PTIGVYPOASVPLTLAQWEPVLPYPEAHNPASLTMVYOTPVPHDPMPMSRLSPTQTS 120

66 PTIGVYPOASVPLTLAQWEPVLPYPEAHNPASLTMVYOTPVPHDPMPMSRLSPTQTS 120

67 PTIGVYPOASVPLTLAQWEPVLPYPEAHNPASLTMVYOTPVPHDPMPMSRLSPTQTS 120

67 PTIGVYPOASVPLTLAQWEPVLPYPEAHNPASLTMVYOTPVPHDPMPMSRLSPTQTS 120

68 PTIGVYPOASVPLTLAQWEPVLPYPEAHNPASLTMVYOTPVPHDPMPMSRLSPTQTS 120

68 PTIGVYPOASVPLTLAQWEPVLPYPEAHNPASLTMVYOTPVPHDPMPMSRLSPTQTS 120

69 PTIGVYPOASVPLTLAQWEPVLPYPEAHNPASLTMVYOTPVPHDPMPMSRLSPTQTS 120

69 PTIGVYPOASVPLTLAQWEPVLPYPEAHNPASLTMVYOTPVPHDPMPMSRLSPTQTS 120

70 PTIGVYPOASVPLTLAQWEPVLPYPEAHNPASLTMVYOTPVPHDPMPMSRLSPTQTS 120

70 PTIGVYPOASVPLTLAQWEPVLPYPEAHNPASLTMVYOTPVPHDPMPMSRLSPTQTS 120

71 PTIGVYPOASVPLTLAQWEPVLPYPEAHNPASLTMVYOTPVPHDPMPMSRLSPTQTS 120

71 PTIGVYPOASVPLTLAQWEPVLPYPEAHNPASLTMVYOTPVPHDPMPMSRLSPTQTS 120

72 PTIGVYPOASVPLTLAQWEPVLPYPEAHNPASLTMVYOTPVPHDPMPMSRLSPTQTS 120

73 PTIGVYPOASVPLTLAQWEPVLPYPEAHNPASLTMVYOTPVPHDPMPMSRLSPTQTS 120

74 PTIGVYPOASVPLTLAQWEPVLPYPEAHNPASLTMVYOTPVPHDPMPMSRLSPTQTS 120

75 PTIGVYPOASVPLTLAQWEPVLPYPEAHNPASLTMVYOTPVPHDPMPMSRLSPTQTS 120

PD 02-JAN-2003.

XX XX PR 11-JUL-2001; 2001US-0904011.

XX XX PR 10-SEP-1998; 98WO-US18824.

XX XX PR 14-SEP-1998; 98WO-US19177.

XX XX PR 16-SEP-1998; 98WO-US19330.

XX XX PR 17-SEP-1998; 98WO-US19437.

XX XX PR 01-DEC-1998; 98WO-US25108.

XX XX PR 08-SEP-1999; 99WO-US20594.

XX XX PR 13-SEP-1999; 99WO-US20944.

XX XX PR 15-SEP-1999; 99WO-US21090.

XX XX PR 15-SEP-1999; 99WO-US21547.

XX XX PR 29-NOV-1999; 99WO-US22114.

XX XX PR 30-NOV-1999; 99WO-US23313.

XX XX PR 01-DEC-1999; 99WO-US23301.

XX XX PR 02-DEC-1999; 99WO-US23564.

XX XX PR 20-DEC-1999; 99WO-US30911.

XX XX PR 20-DEC-1999; 99WO-US31999.

XX XX PR 20-FEB-2000; 2000WO-US0219.

XX XX PR 11-FEB-2000; 2000WO-US03565.

XX XX PR 22-FEB-2000; 2000WO-US0414.

XX XX PR 24-FEB-2000; 2000WO-US05004.

XX XX PR 02-MAR-2000; 2000WO-US05841.

XX XX PR 20-MAR-2000; 2000WO-US0377.

XX XX PR 22-MAY-2000; 2000WO-US0439.

XX XX PR 02-OCT-2000; 2000WO-US13264.

XX XX PR 24-AUG-2000; 2000WO-US20710.

XX XX PR 17-SEP-1997; 97US-059113P.

XX XX PR 17-SEP-1997; 97US-059115P.

XX XX PR 17-SEP-1997; 97US-059117P.

XX XX PR 17-SEP-1997; 97US-059119P.

XX XX PR 17-SEP-1997; 97US-059121P.

XX XX PR 17-SEP-1997; 97US-059122P.

XX XX PR 17-SEP-1997; 97US-059184P.

XX XX PR 18-SEP-1997; 97US-059263P.

XX XX PR 15-OCT-1997; 97US-062125P.

XX XX PR 17-OCT-1997; 97US-062285P.

XX XX PR 17-OCT-1997; 97US-062287P.

XX XX PR 21-OCT-1997; 97US-063486P.

XX XX PR 24-OCT-1997; 97US-062814P.

XX XX PR 24-OCT-1997; 97US-063016P.

XX XX PR 24-OCT-1997; 97US-063045P.

XX XX PR 24-OCT-1997; 97US-063120P.

XX XX PR 24-OCT-1997; 97US-063121P.

XX XX PR 24-OCT-1997; 97US-063127P.

XX XX PR 27-OCT-1997; 97US-06327P.

XX XX PR 27-OCT-1997; 97US-063329P.

XX XX PR 28-OCT-1997; 97US-06341P.

XX XX PR 28-OCT-1997; 97US-06354P.

XX XX PR 28-OCT-1997; 97US-06354P.

XX XX PR 28-OCT-1997; 97US-06354P.

XX XX PR 29-OCT-1997; 97US-063738P.

XX XX PR 29-OCT-1997; 97US-064215P.

XX XX PR 31-OCT-1997; 97US-063870P.

XX XX PR 03-NOV-1997; 97US-064103P.

XX XX PR 07-NOV-1997; 97US-064809P.

XX XX PR 07-NOV-1997; 97US-065186P.

PR 17-NOV-1997; 97US-065846P.
 PR 18-NOV-1997; 97US-065639P.
 PR 21-NOV-1997; 97US-066120P.
 PR 21-NOV-1997; 97US-066346P.
 PR 24-NOV-1997; 97US-066453P.
 PR 24-NOV-1997; 97US-066466P.
 PR 24-NOV-1997; 97US-066511P.
 PR 24-NOV-1997; 97US-066770P.
 PR 24-NOV-1997; 97US-066772P.
 PR 18-SEP-2000; 2000US 0665350.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Ashkenazi A, Bottstein D, Desnoyers L, Eaton DL, Ferrara N, Goddard A, Gofraro E, Fong S, Gao W, Gerber H, Gerritsen ME, Godowski PJ, Grimaldi JC, Gurney AL, Hillian KJ, Klijavin IJ, Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Williams PM, Wood WI;
 PI WPI; 2003-329602/31.
 XX
 PR New transmembrane polypeptides and nucleic acids encoding the polypeptides, useful in gene therapy, in chromosome identification, as chromosome markers, in generating probes and in tissue typing - DR N-PSDB; ACGA6013.
 XX
 PR PT
 PT XX
 PS Claim 12; Fig 9; 484pp; English.
 XX
 CC The invention relates to an isolated nucleic acid with at least 80% nucleic acid sequence identity to a nucleotide sequence encoding one of 61 secreted/transmembrane polypeptides, or PRO polypeptides or encoding a PRO protein extracellular domain. Also included are a vector comprising the PRO nucleic acid, a host cell comprising the vector, producing a PRO polypeptide (by culturing the host cell for the expression of the PRO polypeptide, and recovering the PRO polypeptide from the cell culture), an isolated PRO polypeptide (having at least 80% sequence identity to: (a) an amino acid sequence selected from the 61 PRO proteins; (b) an amino acid sequence encoded by a nucleic acid molecule deposited with an ATCC number (detailed in the specification); or (c) an extracellular domain of a PRO polypeptide or to a PRO polypeptide lacking its associated signal peptide), a chimaeric molecule comprising a PRO polypeptide of fused to a heterologous amino acid sequence, an anti-PRO antibody, detecting a PRO245 or PRO1868 in a sample suspected of containing the polypeptide, linking a bioactive molecule to a cell expressing a PRO245 or PRO1868 and modulating at least one biological activity of a cell expressing a PRO245 or PRO1868. Nucleic acids which encode PRO can be used to generate either transgenic animals or knock-out animals which may be used in the development and screening of therapeutically useful reagents. The nucleic acids may also be used in gene therapy, in chromosome identification, as chromosome markers, or in generating probes. The PRO polypeptides are useful as molecular markers for protein electrophoresis, and the isolated nucleic acids may be used for recombinantly expressing those markers. The PRO polypeptides and nucleic acids may also be used in tissue typing. Anti-PRO antibodies are useful in diagnostic assays for PRO, and in affinity purification of PRO from recombinant cell culture or natural sources. The present sequence represents a PRO protein.
 XX
 SQ Sequence 189 AA:
 Query Match 100 %; Score 1045; DB 24; Length 189;
 Best Local Similarity 100.0%; Pred. No. 5.3e-86; Matches 189; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MTHRITTWARRTSRAVTPTCATPAGMPMCSRLLPSTRCLSACCSGGDPAASYRLWQAPLQ 60
 1 MTHRITTWARRTSRAVTPTCATPAGMPMCSRLLPSPRSCLHSACCSGGDPAASYRLWQAPLQ 60
 QY 61 PTLGVYPOASVPLTLDAQWNPVLYFEAHPWASLTYVCTVPHPPPPMALSRTPQIS 120
 61 PTLGVYPOASVPLTLDAQWNPVLYFEAHPWASLTYVCTVPHPPPPMALSRTPQIS 120
 Db 15-OCT-1997; 97US-062285P.
 PR 18-SEP-1997; 97US-0591266P.
 PR 17-OCT-1997; 97US-062285P.
 PR 17-OCT-1997; 97US-062287P.

121 SSBTPPADGPSNPLCCCFHGFATSTINPVLRLHFOEAFPAHPIYDLSQWWSVSPAPS 180
 181 RSGAARRAQ 189
 181 RGOAARRAQ 189
 RESULT 5
 ABU6748
 ID ABU6748 standard; Protein; 189 AA.
 XX
 AC ABU6748;
 XX
 DR 29-MAY-2003 (first entry)
 XX DE Human secreted protein PRO232.
 XX KW Human; gene therapy; mucosal lesion; ulcer; enterocolitis; skin disease; psoriasis; cancer; lung cancer; colon cancer; nerve cell disease; Alzheimer's disease; Parkinson's disease; Usher syndrome; angiogenesis; atrophia areata; inflammatory disease; asthma; rheumatoid arthritis; ischaemia.
 XX KW Homo sapiens.
 XX OS Homo sapiens.
 PS US2003023054-A1.
 XX
 PD 30-JAN-2003.
 XX PR 16-JUL-2001; 2001US-0906742.
 PF XX
 PR 10-SEP-1998; 99WO-US18824.
 PR 14-SEP-1998; 99WO-US19117.
 PR 16-SEP-1998; 99WO-US19330.
 PR 17-SEP-1998; 99WO-US19437.
 PR 01-DEC-1998; 99WO-US25108.
 PR 08-SEP-1999; 99WO-US220594.
 PR 13-SEP-1999; 99WO-US20944.
 PR 15-SEP-1999; 99WO-US21090.
 PR 15-SEP-1999; 99WO-US22147.
 PR 05-OCT-1999; 99WO-US23089.
 PR 29-NOV-1999; 99WO-US28214.
 PR 30-NOV-1999; 99WO-US22813.
 PR 01-DEC-1999; 99WO-US28301.
 PR 02-DEC-1999; 99WO-US28554.
 PR 02-DEC-1999; 99WO-US28865.
 PR 16-DEC-1999; 99WO-US30095.
 PR 20-DEC-1999; 99WO-US30911.
 PR 20-DEC-1999; 99WO-US30999.
 PR 05-JAN-2000; 2000WO-US0219.
 PR 11-FEB-2000; 2000WO-US0355.
 PR 22-FEB-2000; 2000WO-US04414.
 PR 24-FEB-2000; 2000WO-US05004.
 PR 02-MAR-2000; 2000WO-US05841.
 PR 20-MAR-2000; 2000WO-US07377.
 PR 30-MAR-2000; 2000WO-US08439.
 PR 22-MAY-2000; 2000WO-US14042.
 PR 02-JUN-2000; 2000WO-US15264.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 17-SEP-1997; 97US-059113P.
 PR 17-SEP-1997; 97US-059115P.
 PR 17-SEP-1997; 97US-059117P.
 PR 17-SEP-1997; 97US-059121P.
 PR 17-SEP-1997; 97US-059122P.
 PR 17-SEP-1997; 97US-059124P.
 PR 18-SEP-1997; 97US-059263P.
 PR 18-SEP-1997; 97US-059266P.
 PR 15-OCT-1997; 97US-062125P.
 PR 17-OCT-1997; 97US-062285P.
 PR 17-OCT-1997; 97US-062287P.

121 SSDTPPADGPSNPLCCCFHGFATSTINPVLRLHFOEAFPAHPIYDLSQWWSVSPAPS 180

PR	21-OCT-1997;	97US-063486P.	CC	Polypeptides by recombinant techniques, and in generating either transgenic animals or knock-out animals which, in turn, are useful in the development and screening of therapeutically useful reagents.
PR	24-OCT-1997;	97US-062814P.	CC	CC
PR	24-OCT-1997;	97US-062816P.	CC	CC
PR	24-OCT-1997;	97US-063045P.	CC	CC
PR	24-OCT-1997;	97US-063120P.	CC	CC
PR	24-OCT-1997;	97US-063121P.	CC	treating a condition responsive to the polypeptide or antibody, such as
PR	24-OCT-1997;	97US-063127P.	CC	mucosal lesions e.g. ulcers and enterocolitis, skin disease e.g. psoriasis, cancer e.g. lung cancer and colon cancer, nerve cell disease e.g. Alzheimer's disease and Parkinson's disease, Usher syndrome, atrophy aerea, angiogenesis, inflammatory disease e.g. asthma and
PR	27-OCT-1997;	97US-06328P.	CC	rheumatoid arthritis, ischaemia, and in various diagnostic assays. The present sequence represents the amino acid sequence of a PRO polypeptide.
PR	27-OCT-1997;	97US-063329P.	CC	XX
PR	28-OCT-1997;	97US-063341P.	CC	XX
PR	28-OCT-1997;	97US-063342P.	CC	XX
PR	28-OCT-1997;	97US-063344P.	CC	XX
PR	28-OCT-1997;	97US-063349P.	CC	XX
PR	28-OCT-1997;	97US-063350P.	CC	XX
PR	28-OCT-1997;	97US-063354P.	CC	XX
PR	29-OCT-1997;	97US-063435P.	CC	XX
PR	29-OCT-1997;	97US-063704P.	CC	XX
PR	29-OCT-1997;	97US-063732P.	CC	XX
PR	29-OCT-1997;	97US-063734P.	CC	XX
PR	29-OCT-1997;	97US-063735P.	CC	XX
PR	29-OCT-1997;	97US-063738P.	CC	XX
PR	29-OCT-1997;	97US-064215P.	CC	XX
PR	31-OCT-1997;	97US-063870P.	CC	XX
PR	31-OCT-1997;	97US-064103P.	CC	XX
PR	03-NOV-1997;	97US-064248P.	CC	XX
PR	07-NOV-1997;	97US-064809P.	CC	XX
PR	12-NOV-1997;	97US-065186P.	CC	XX
PR	17-NOV-1997;	97US-065846P.	CC	XX
PR	18-NOV-1997;	97US-065963P.	CC	XX
PR	21-NOV-1997;	97US-066120P.	CC	XX
PR	21-NOV-1997;	97US-066364P.	CC	XX
PR	24-NOV-1997;	97US-066453P.	CC	XX
PR	24-NOV-1997;	97US-066511P.	CC	XX
PR	24-NOV-1997;	97US-066770P.	CC	XX
PR	25-NOV-1997;	97US-066840P.	CC	XX
PR	12-DEC-1997;	97US-066425P.	CC	XX
PR	04-JUN-1998;	98US-08026P.	CC	XX
PR	10-SEP-1998;	98US-099803P.	CC	XX
PR	14-SEP-1998;	98US-100262P.	CC	XX
PR	15-SEP-1998;	98US-100858P.	CC	XX
PR	13-OCT-1998;	98US-104080P.	CC	XX
PR	20-NOV-1998;	98US-109304P.	CC	XX
PR	22-DEC-1998;	98US-113296P.	CC	XX
PR	07-JUL-1999;	99US-143048P.	CC	Human: PRO; secreted; transmembrane; pharmaceutical; diagnostic; biosensor; bioreactor; therapeutic; hyperplasia;
PR	26-JUL-1999;	99US-145698P.	CC	endometriosis; cancer; tumour; ischaemia; coronary arterial disease; polycystic kidney disease; renal failure; inflammatory response; asthma; rheumatoid arthritis; psoriasis; multiple sclerosis; gene therapy; cysticstatic; gynecological; cardiant; nephrotropic; hepatotropic; antiinflammatory.
PR	28-JUL-1999;	99US-146222P.	CC	OS
PR	18-SEP-2000;	2000US-0665350.	CC	Homo sapiens.
PA	(GETH) GENENTECH INC.	XX	XX	US2002160374-A1.
XX	XX	XX	XX	PD 31-OCT-2002.
DR	WPI; 2003-331485/31.	XX	XX	12-JUL-2001: 2001US-0905291.
DR	N-PSDB: ACA05351.	XX	XX	10-SEP-1998: 98WO-US18824.
PT	Sixty one isolated nucleic acids encoding a PRO polypeptide, e.g. antisense RNA and DNA, and in treating cancer and Alzheimer's disease.	XX	PR	14-SEP-1998: 98WO-US19177.
PT	PRO245 or PRO1868, useful in chromosome and gene mapping, in generating antisense RNA and DNA, and in treating cancer and Alzheimer's disease.	XX	PR	16-SEP-1998: 98WO-US19330.
PS	Example 4; Fig 9: 481pp; English.	XX	PR	17-SEP-1998: 98WO-US19437.
CC	The invention relates to sixty one nucleic acids encoding PRO polypeptides (secreted and transmembrane). The polynucleotide is useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy. The polynucleotide may also be used in preparing PRO	CC	PR	01-DEC-1998: 98WO-US25080.
CC	CC	CC	PR	08-SEP-1999: 99WO-US20534.
CC	CC	CC	PR	13-SEP-1999: 99WO-US2044.
CC	CC	CC	PR	15-SEP-1999: 99WO-US21990.
CC	CC	CC	PR	15-SEP-1999: 99WO-US21947.
CC	CC	CC	PR	05-OCT-1999: 99WO-US23089.
CC	CC	CC	PR	29-NOV-1999: 99WO-US28313.

PN US2002132240-A1.
 XX
 PD 19-SEP-2002.
 XX
 PR 18-JUL-2001; 2001US-0909320.
 XX
 PR 10-SEP-1998; 98WO-US18824.
 PR 14-SEP-1998; 98WO-US19177.
 PR 16-SEP-1998; 98WO-US19330.
 PR 17-SEP-1998; 98WO-US19437.
 PR 01-DEC-1998; 98WO-US25108.
 PR 08-SEP-1999; 99WO-US20594.
 PR 13-SEP-1999; 99WO-US20344.
 PR 15-SEP-1999; 99WO-US21090.
 PR 15-SEP-1999; 99WO-US21547.
 PR 05-OCT-1999; 99WO-US23089.
 PR 01-DEC-1999; 99WO-US28301.
 PR 02-DEC-1999; 99WO-US28564.
 PR 16-DEC-1999; 99WO-US28565.
 PR 20-DEC-1999; 99WO-US30911.
 PR 20-DEC-1999; 99WO-US3099.
 PR 06-JAN-2000; 2000WO-US00219.
 PR 11-FEB-2000; 2000WO-US03565.
 PR 22-FEB-2000; 2000WO-US04414.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 17-SEP-1997; 97US-059113P.
 PR 17-SEP-1997; 97US-059115P.
 PR 15-OCT-1997; 97US-059117P.
 PR 17-OCT-1997; 97US-062285P.
 PR 17-OCT-1997; 97US-062287P.
 PR 24-OCT-1997; 97US-062814P.
 PR 24-OCT-1997; 97US-062816P.
 PR 24-OCT-1997; 97US-062816P.
 PA (GETH) GENENTECH INC.
 XX
 PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DJ, Ferrara N;
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritzen ME, Goddard A;
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillian KJ, Kljavin LJ;
 PI Matier JP, Pan J, Paoni NF, Roy MA, Stewart TR, Tumas D;
 PI Williams PM, Wood WI;
 XX
 DR WPI; 2003-147434/14.
 DR N-PSDB; ABX71461.
 XX
 PT New PRO polypeptides and nucleic acid molecules, useful in diagnosing
 or treating inflammatory diseases, organ failure, atherosclerosis,
 cardiac injury, infertility, cancer, AIDS, Alzheimer's disease or
 Parkinson's disease -
 XX
 PS Claim 12; Fig 9; 473pp; English.
 XX
 CC The invention relates to an isolated PRO polypeptide having at least 80%
 amino acid sequence identity to: (a) any one of 61 fully defined amino
 acid sequences given in the specification (appearing as ABUS4347-
 ABUS54407); (b) an amino acid sequence encoded by the nucleotide sequence
 deposited under American Type Culture Collection (accession numbers
 listed in the specification); (c) any one of the PRO sequences which
 lacks its associated signal peptide; (d) an extracellular domain of the
 PRO polypeptide with its associated signal peptide; or (e) an
 extracellular domain of the PRO polypeptide which lacks its associated
 signal peptide. Also include are the nucleic acids encoding the PRO
 polypeptides, vectors, host cells and anti-PRO antibodies.
 The PRO polypeptides and nucleic acids are useful in diagnosing
 or treating enterocolitis, gastrointestinal ulceration, skin diseases
 associated with abnormal keratinocyte differentiation, e.g. psoriasis
 or epithelial cancers such as squamous cell carcinoma, Alzheimer's
 disease, Parkinson's disease, amyotrophic lateral sclerosis,
 inflammatory diseases, e.g. rheumatoid arthritis, asthma or multiple
 sclerosis, organ failure, atherosclerosis, cardiac injury, infertility,
 XX

CC birth defects, premature aging, AIDS, cancer, diabetic complications,
 CC or mutations in general. The polypeptides are also useful for wound
 repair and associated therapies concerned with re-growth of tissue. The
 CC nucleotide sequences may be used as hybridisation probes in chromosome
 CC and gene mapping, or in generating antisense RNA and DNA. PRO nucleic
 acids are also useful in preparing PRO polypeptides, in assays to
 CC identify other proteins or molecules involved in binding reaction, to
 CC generate transgenic animals or knockout animals, which in turn are
 CC useful in the development and screening of therapeutically useful
 reagents, for chromosome identification, and tissue typing. The PRO
 CC polypeptides and nucleic acid molecules are also useful in gene
 CC therapy, and as molecular weight markers for protein electrophoresis
 CC purposes. The anti-PRO antibodies may be used in diagnostic assays for
 CC PRO, or for the affinity purification of PRO from recombinant cell
 CC culture or natural sources. The present sequence represents a PRO
 CC polypeptide.
 XX

SQ Sequence 189 AA:
 Query Match 100.0%; Score 1045; DB 24; Length 189;
 Best Local Similarity 100.0%; Pred. No. 5.3e-86;
 Matches 189; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Matches 189; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 MTHRTTWARRTSRAVPTCATPAGPAPCSRLPSLCSLHSACCSDPASYRLMCAPIO 60
 Db 1 MTHRTTWARRTSRAVPTCATPAGPAPCSRLPSLCSLHSACCSDPASYRLMCAPIO 60
 Qy 61 PRIGVWVQASVPLTLAQWEPVLPVAPRWAQMLVYCTVPHPPPMALSRTPQIS 120
 Db 61 PRIGVWVQASVPLTLAQWEPVLPVAPRWAQMLVYCTVPHPPPMALSRTPQIS 120
 Qy 121 SSTDTPPADGSNSPLCCFHGPASFSLNPVLRHLFFQEAFFAHPVIDLSQLSQWSVSPAPS 180
 Db 121 SSTDTPPADGSNSPLCCFHGPASFSLNPVLRHLFFQEAFFAHPVIDLSQLSQWSVSPAPS 180
 Qy 181 RQQLRRAQ 189
 Db 181 RQQLRRAQ 189

RESULT 8
 AAY6174
 ID AAY6174 standard; Protein; 187 AA.
 XX
 AC AAY6174;
 XX
 DT 14-FEB-2000 (first entry).
 XX
 DE Human bladder tumour EST encoded protein 32.
 XX
 KW Expressed sequence tag; human; bladder; tumour; cancer; cytostatic;
 XX
 KW treatment; gene therapy; EST.
 XX
 OS Homo sapiens.
 XX
 PN DE19818619-A1.
 XX
 PD 28-OCT-1999.
 XX
 PR 21-APR-1998; 98DE-1018619.
 XX
 PR 21-APR-1998; 98DE-1018619.
 XX
 PR (META-) METAGEN GES GENOMFORSCHUNG MBH.
 XX
 PI Rosenthal A, Specht T, Hinzmann B; Schmitt A, Pilarsky C, Dahl E;
 XX
 DR WPI; 1999-612028/53.
 XX
 PT New nucleic acid sequences expressed in bladder tumor tissue, and identification
 PT of therapeutic agents -
 XX

XX

Query Match		Score 998: DB 20: Length 187:	
Best Local Similarity		Pred. NO. 87a-82;	
Matches	182; Conservative	0; Mismatches	4; Indels
QY	4 RTTWWARRTSRAVTPCTCAMPAGPMPCSRULPPSLKCSLHSACCSDGAPASYRLWGAQPLT	67.8%	95.5%; 67.8%;
Db	2 RAARGARRTSRAVTPCTCAMPAGPMPCSRULPPSLKCSLHSACCSDGAPASYRLWGAQPLT		61
QY	64 GYVPOASVPLTLAQMEPVLYRAPHNALSITMVCYTPVPHDPMALSRPTPROLISSD	63	
Db	62 GYVPOASVPLTLAQMEPVLYRAPHNALSITMVCYTPVPHDPMALSRPTPROLISSD		121
QY	124 TDPPADGPSNPLCCCFRGPAFSTLNPVHLFQEAFAHAPIYDLSQWNSWSPAPSRGQ	183	
Db	122 TDPPADGPSNPLCCCFRGPAFSTLNPVHLFQEAFAHAPIYDLSQWNSWSPAPSRGQ		181
QY	184 ALPRRAQ 189		
Db	182 ALRRAQ 187		

RESULT 9
ABU18375

ABJ18375; ABJ18375 standard; protein; 1518 AA.
AC XX XX XX

KW metastatic; breast cancer; breast specific; human.
XX
OS
XX
Homo sapiens.

PN WO200277232-A2.
XX
PD 03-OCT-2002.
YY

PF 21-NOV-2001; 2001WO-US43815.
XX
PR 22-NOV-2000; 2000US-252599.

PA (DIAD-) DIADEXUS INC.
XX
PI Salceda S, Macina RA, Recipon H, Pluta J, Sun Y, Liu C;

XX DR. WPI; 2003-018927/01.
XX
PT New isolated nucleic acid molecule, useful for treating breast cancer.

DT 14-APR-2003 (first entry)

XX DE Human testes-derived DKFzpthes3_2a11 homologue #20.

XX KW Human; gene therapy; vaccine; disease treatment; detection.

XX OS Homo sapiens.

XX PN WO200112659-A2.

XX PD 22-FEB-2001.

XX PF 18-AUG-2000; 2000WO-1B01496.

XX PR 18-AUG-1999; 990US-014999.

XX PR 28-SEP-1999; 99US-015603.

XX PA (GEHU-) GERMAN HUMAN GENOME PROJECT.

XX PI Wiemann S;

XX DR WPI; 2001-327840/34.

XX PT Nucleic acids having the sequences of clones isolated from libraries of different human tissues, useful in recombinant DNA methodologies

XX PS Example III; Page 774-775; 1095pp; English.

XX CC This invention describes novel polynucleotides and polypeptides isolated from human cDNA libraries which can be used for gene therapy or in vaccines. The polynucleotides of the invention and antibodies encoded by them may be used in the prevention, diagnosis and treatment of diseases associated with inappropriate polypeptide expression. The products of these inventions may also be used to identify modulators of expression and activity and to down regulate expression and activity. The antibodies of the invention may also be used as diagnostic agents for detecting the presence of polypeptides in samples. This sequence represents a homologue of a polypeptide described in the disclosure of the invention.

XX CC

XX Sequence 395 AA;

QY Best Local Similarity 11.2%; Score 117.5; DB 22; Length 395; Matches 41; Conservative 23; Mismatches 98; Indels 15; Gaps 5

QY 5 TTTWARTTSRAVTPTCAATPGPMPCRSRLPSLRCISLHSACCGDPAWSYRILWGPLQPTIG 64

QY ||| : | : | | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |

Db 165 TTPSPPTPTTTPPTTTPSPPTTTPSPPTTTPPTTTPPTTTPSPPTTTPPTTTPP--PPTT 2277

QY 65 WPVQASVPLL-TDIAQWEPVPLVPEAHPNASLTMVCTPVPHRDPPEPMAISRTPRQISSL 1222

QY ||| : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |

Db 223 PSPPPTTPTPPTSTTLPPTTSPPTTTTP--PPTTTPSP--TTTSPPTTPT 2777

QY 123 DTPDPTRDGSPNPLCCGCFHGAFASTUNPVHLFPEQAFAPAHPIYDLSQWSVWSRAP 179

QY ||| : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |

Db 278 TTPPPPTTTPSPPTTTPSPPTTTPPTTTPP-----SPTTSPSPPTTPTTSPSTT 328

AAY66174
ID AAY66174 standard; Protein; 187 AA.
XX
AC AAY66174;
XX
DT 14-FEB-2000 (first entry)
XX
DE Human bladder tumour EST encoded protein 32.
XX
KW Expressed sequence tag; human; bladder; tumour; cancer; cytostatic;
KW treatment; gene therapy; EST.
XX
OS Homo sapiens.
XX
PN DE19818619-A1.
XX
PD 28-OCT-1999.
XX
PF 21-APR-1998; 98DE-1018619.
XX
PR 21-APR-1998; 98DE-1018619.
XX
PA (META-) METAGEN GES GENOMFORSCHUNG MBH.
XX
PI Rosenthal A, Specht T, Hinzmann B, Schmitt A, Pilarsky C, Dahl E;
XX
DR WPI; 1999-612028/53.
XX
PT New nucleic acid sequences expressed in bladder tumor tissue, and
PT derived polypeptides, for treatment of bladder tumor and identification
PT of therapeutic agents -
XX

PS Claim 23; Page 111; 132pp; German.

XX
CC This invention describes novel polypeptide fragments (I) and the
CC polynucleotides (II) that encode them that are highly expressed in a
CC human bladder tumour and which have cytostatic activity. (II) are used
CC for recombinant expression of (I) and to isolate complete genes. (I) are
CC used to identify agents suitable for treatment of bladder cancer, to
CC directly treat this form of cancer (including expression from gene
CC therapy vectors) or are used in a preparation for cancer treatment. (I)
CC is also used for the generation of specific antibodies. (II) are
CC identified by assembling ESTs (expressed sequence tags) from a
CC particular tissue type before comparison of expression patterns. This
CC allows a significantly longer fragment of the gene to be revealed, and
CC therefore reduces the number of failures associated with the fact that
CC ESTs from different libraries may represent different parts of the same
CC unknown gene, distorting the estimated frequency of occurrence in a
CC particular tissue. AAY66143-Y66198 represent protein fragments encoded by
CC the human bladder tumour cDNA library derived expressed sequence tag
XX (EST) fragments represented in AAZ43260-Z43309.

SQ Sequence 187 AA;

Query Match 95.5%; Score 998; DB 20; Length 187;
Best Local Similarity 97.8%; Pred. No. 8.7e-82;
Matches 182; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 4 RTTTWARRTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPLQPTL 63
Db 2 RAARGARRTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPLQPTL 61
Qy 64 GVVPQASVPLLTDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQISSSD 123
Db 62 GVVPQASVPLLTDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQISSSD 121
Qy 124 TDPPADGPSNPLCCCFHGPafSTLNpVLRHLPQEAFPAHPIYDLSQVWSVVSPAPSRGQ 183
Db 122 TDPPADGPSNPLCCCFHGPafSTLNpVLRHLPQEAFPAHPIYDLSQVWSVVSPAPSRGQ 181
Qy 184 ALRRAQ 189
Db 182 ALRRAQ 187